drugset
drugset / Trial / NCT04984369

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

NCT04984369 ↗

Phase 2 Unknown 50 enrolled Shanghai Henlius Biotech
Non-randomizedParallel-groupOpen-labelTreatment

Summary

An open, multicenter phase II clinical study to evaluate safety and efficacy of HLX208 (BRAF V600E inhibitor) combined with cetuximab for metastatic colorectal cancer (mCRC) with BRAF V600E Mutation after first-line treatment

Timeline

Start
2021-08-11
Primary completion
2024-06-15
Completion
2025-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody 500 mg/m2 Intravenous
Subject HLX208 Unknown 450 mg Oral
Subject HLX208 Unknown 600 mg Oral
Subject HLX208 Unknown 900 mg Oral

Indications

No indication recorded.